Hikma Pharmaceuticals (HIK) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic overview and financial performance

• Achieved 7% core revenue CAGR and 8% core EBITDA CAGR over five years, maintaining EBITDA margins above 27% and strong cash generation.

• Operates three divisions: injectables, branded, and generics, with injectables as the largest profit contributor.

• CEO Riad Mishlawi presented a strategy focused on growth, diversification, and operational excellence, guided by four pillars: platform strength, portfolio diversity, growth strategy, and financial discipline.

• Maintains a robust balance sheet with $1.5 billion in firepower, low leverage (1.3x net debt/EBITDA as of June 2024), and 17.7% ROIC.

• Raised group guidance for 2024, targeting 6–8% revenue growth and $700–730m core operating profit, with confidence in continued growth into 2025.

Business segment updates and growth drivers

• Injectables division delivers high single-digit growth, aiming for double digits, supported by the Xellia acquisition and capacity expansion in multiple regions.

• Branded business in MENA benefits from local manufacturing, regulatory advantages, and strong business development, driving 6%-8% growth.

• Generics division shifted from stability to growth focus, investing in R&D and contract manufacturing to support future expansion.

• Portfolio includes over 760 products and 29 manufacturing plants, with more than 300 pipeline products and 75% of top 20 projects planned as first-to-market/generic in the next five years.

• Targeting 6–7% of group revenue for R&D, focusing on complex and differentiated products, and expanding the ex-US pipeline.

Operational and market insights

• Injectables portfolio is highly diversified, with no single product exceeding 7% of revenue.

• Expanded market reach in Europe, launched 59 products in 1H24, and saw significant growth in oncology (43%) and diabetes (50%) revenues.

• GLP-1s and compounding present new growth opportunities, with recent successful launch of liraglutide and expanding hospital client base.

• U.S. injectable drug shortages persist due to pricing models and high capacity costs, with little recent improvement.

• Contract manufacturing in generics helps cover fixed costs and supports margin stability, while capital allocation prioritizes R&D, facility upgrades, and potential share buybacks.